{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T02:56:58Z","timestamp":1795057018528,"version":"4.10.2"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T00:00:00Z","timestamp":1754179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001655","name":"Deutscher Akademischer Austauschdienst","doi-asserted-by":"publisher","award":["57740018"],"award-info":[{"award-number":["57740018"]}],"id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["514201724"],"award-info":[{"award-number":["514201724"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021828","name":"DAAD Regional Office New York","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021828","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019186","name":"HORIZON EUROPE Innovative Europe","doi-asserted-by":"publisher","award":["945151"],"award-info":[{"award-number":["945151"]}],"id":[{"id":"10.13039\/100019186","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.euroneuro.2025.08.003","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T16:51:06Z","timestamp":1756659066000},"page":"13-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8589-7384","authenticated-orcid":false,"given":"Natalia E.","family":"Fares-Otero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7301-9157","authenticated-orcid":false,"given":"Monika","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Laatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7016-2687","authenticated-orcid":false,"given":"Mathias","family":"Harrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teuntje","family":"Pelgrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6876-518X","authenticated-orcid":false,"given":"Alexandra","family":"Philipsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7135-762X","authenticated-orcid":false,"given":"Urs","family":"Heilbronner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-0053","authenticated-orcid":false,"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roos","family":"van Westrhenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2025.08.003_bib0001","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2147\/NDT.S312966","article-title":"Effect of pharmacogenetic-based decision support tools in improving depression outcomes: a systematic review","volume":"17","author":"Aboelbaha","year":"2021","journal-title":"Neuropsychiatr Dis Treatm"},{"issue":"9619","key":"10.1016\/j.euroneuro.2025.08.003_bib0002","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(08)60505-X","article-title":"EQUATOR: reporting guidelines for health research","volume":"371","author":"Altman","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0003","series-title":"Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition)","year":"2013"},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104965","article-title":"Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: systematic review and meta-analysis of randomised controlled trials","volume":"144","author":"Arnone","year":"2023","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"4","key":"10.1016\/j.euroneuro.2025.08.003_bib0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid. Based. Ment. Health"},{"issue":"3","key":"10.1016\/j.euroneuro.2025.08.003_bib0006","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41431-023-01347-3","article-title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics","volume":"32","author":"Beunk","year":"2024","journal-title":"Eur. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.euroneuro.2025.08.003_bib0007","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I2 is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res. Synth. Methods"},{"issue":"1","key":"10.1016\/j.euroneuro.2025.08.003_bib0008","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2217\/pgs-2018-0142","article-title":"Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials","volume":"20","author":"Bousman","year":"2019","journal-title":"Pharmacogenomics."},{"issue":"1","key":"10.1016\/j.euroneuro.2025.08.003_bib0009","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/a-1288-1061","article-title":"Review and consensus on pharmacogenomic testing in psychiatry","volume":"54","author":"Bousman","year":"2021","journal-title":"PharmacoPsychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0010","first-page":"2023","article-title":"Chapter 7: considering bias and conflicts of interest among the included studies","author":"Boutron","year":"2023","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.4"},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0011","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/16501960410015380","article-title":"Identifying the concepts contained in outcome measures of clinical trials on depressive disorders using the International Classification of Functioning, Disability and Health as a reference","volume":"44","author":"Brockow","year":"2004","journal-title":"J. Rehabil. Med."},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0012","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1741-7015-9-90","article-title":"Cross-national epidemiology of DSM-IV major depressive episode","volume":"9","author":"Bromet","year":"2011","journal-title":"BMC. Med."},{"issue":"10","key":"10.1016\/j.euroneuro.2025.08.003_bib0013","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41431-021-01004-7","article-title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs","volume":"30","author":"Brouwer","year":"2022","journal-title":"Eur. J. Hum. Genet.: EJHG"},{"issue":"6","key":"10.1016\/j.euroneuro.2025.08.003_bib0014","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/cpt.2748","article-title":"Pharmacogenomic testing and depressive symptom remission: a systematic review and meta-analysis of prospective","volume":"112","author":"Brown","year":"2022","journal-title":"Clin. Pharmacol. Ther"},{"issue":"8","key":"10.1016\/j.euroneuro.2025.08.003_bib0015","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2217\/pgs-2019-0157","article-title":"The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis","volume":"21","author":"Brown","year":"2020","journal-title":"Pharmacogenomics."},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0016","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.euroneuro.2024.08.002","article-title":"Regarding the meta-analyses of pharmacogenomics-guided antidepressant treatment: a response to Milosavljevic","volume":"88","author":"Bunka","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115102","article-title":"Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: a rapid review and meta-analysis","volume":"321","author":"Bunka","year":"2023","journal-title":"Psychiatry Res."},{"issue":"9665","key":"10.1016\/j.euroneuro.2025.08.003_bib0018","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis","volume":"373","author":"Cipriani","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0019","series-title":"Statistical Power Analysis For the Behavioral Sciences","author":"Cohen","year":"1988"},{"issue":"3","key":"10.1016\/j.euroneuro.2025.08.003_bib0020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014A new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0021","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pnpbp.2018.05.007","article-title":"Pharmacogenetic tests to guide drug treatment in depression: comparison of the available testing kits and clinical trials","volume":"86","author":"Fabbri","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"10440","key":"10.1016\/j.euroneuro.2025.08.003_bib0222","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"Ferrari","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.euroneuro.2025.08.003_bib0022","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.euroneuro.2025.08.003_bib0023","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12955-020-01310-6","article-title":"Quality of life, level of functioning, and its relationship with mental and physical disorders in the elderly: results from the MentDis_ICF65+ study","volume":"18","author":"Grassi","year":"2020","journal-title":"Health Qual. Life Outcomes."},{"issue":"4","key":"10.1016\/j.euroneuro.2025.08.003_bib0024","doi-asserted-by":"crossref","first-page":"469","DOI":"10.9758\/cpn.2018.16.4.469","article-title":"A pharmacogenomic-based antidepressant treatment for patients with major depressive disorder: results from an 8-week, randomized, single-blinded clinical trial","volume":"16","author":"Han","year":"2018","journal-title":"Clin. Psychopharmacol. Neurosci.: Off. Sci. J. Korean Coll. Neuropsychopharmacol."},{"issue":"10","key":"10.1016\/j.euroneuro.2025.08.003_bib0025","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1007\/s11136-019-02214-9","article-title":"A systematic review of quality of life research in medicine and health sciences","volume":"28","author":"Haraldstad","year":"2019","journal-title":"Qual. Life Res.: Int. J. Qual. Life Asp. Treat. Care Rehabil."},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0026","series-title":"Doing Meta-Analysis in R: A Hands-On Guide","author":"Harrer","year":"2022"},{"issue":"4","key":"10.1016\/j.euroneuro.2025.08.003_bib0027","first-page":"1","article-title":"Pharmacogenomic testing for psychotropic medication selection: a systematic review of the Assurex GeneSight psychotropic test","volume":"17","year":"2017","journal-title":"Ont. Health Technol. Assess. Ser."},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0028","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.euroneuro.2024.05.003","article-title":"Meta-analyses of pharmacogenetics-guided antidepressant treatment: reply to milosavljevic","volume":"85","author":"Heilbronner","year":"2024","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2025.08.003_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/bmjment-2023-300978","article-title":"Understanding effect size: an international online survey among psychiatrists, psychologists, physicians from other medical specialities, dentists and other health professionals","volume":"27","author":"Heimke","year":"2024","journal-title":"BMJ Ment. Health"},{"issue":"10","key":"10.1016\/j.euroneuro.2025.08.003_bib0030","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/0269881120922950","article-title":"One (effect) size does not fit at all: interpreting clinical significance and effect sizes in depression treatment trials","volume":"34","author":"Hieronymus","year":"2020","journal-title":"J. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.euroneuro.2025.08.003_bib0031","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/sim.1752","article-title":"Controlling the risk of spurious findings from meta-regression","volume":"23","author":"Higgins","year":"2004","journal-title":"Stat. Med."},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0032","unstructured":"Higgins J.P.T., Thomas J., Chandler J., Cumpston M., Page M.J., Welch V.A., & (Eds.). (2024). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024."},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2022.114482","article-title":"Efficacy and tolerability of therapies set under pharmacogenetic tools suggestions: a systematic review with meta-analysis about mood disorders","volume":"311","author":"Ielmini","year":"2022","journal-title":"Psychiatry Res."},{"issue":"25","key":"10.1016\/j.euroneuro.2025.08.003_bib0034","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1002\/sim.7411","article-title":"The Hartung-Knapp modification for random-effects meta-analysis: a useful refinement but are there any residual concerns?","volume":"36","author":"Jackson","year":"2017","journal-title":"Stat. Med."},{"issue":"3","key":"10.1016\/j.euroneuro.2025.08.003_bib0035","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/jrsm.1240","article-title":"Power analysis for random-effects meta-analysis","volume":"8","author":"Jackson","year":"2017","journal-title":"Res. Synth. Methods"},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2025.08.003_bib0036","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jad.2011.03.046","article-title":"Clinical effectiveness: the importance of psychosocial functioning outcomes","volume":"132","author":"Lam","year":"2011","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.euroneuro.2025.08.003_bib0037","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3109\/09638237.2012.670885","article-title":"Recovery from psychosis: a user informed review of self-report instruments for measuring recovery","volume":"21","author":"Law","year":"2012","journal-title":"J. Ment. Health"},{"issue":"2","key":"10.1016\/j.euroneuro.2025.08.003_bib0038","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2190\/T8EM-C8YH-373N-1UWD","article-title":"Assessing psychiatric impairment in primary care with the Sheehan Disability Scale","volume":"27","author":"Leon","year":"1997","journal-title":"Int. J. Psychiatry Med."},{"issue":"1","key":"10.1016\/j.euroneuro.2025.08.003_bib0039","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"},{"issue":"3","key":"10.1016\/j.euroneuro.2025.08.003_bib0040","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cpr.2009.01.005","article-title":"The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research","volume":"29","author":"McKnight","year":"2009","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0041","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.euroneuro.2024.01.005","article-title":"Current level of evidence for improvement of antidepressant efficacy and tolerability by pharmacogenomic-guided treatment: a systematic review and meta-analysis of randomized controlled clinical trials","volume":"81","author":"Milosavljevi\u0107","year":"2024","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2025.08.003_bib0042","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1186\/s13063-021-05775-8","article-title":"Clinical validation of a combinatorial PharmAcogeNomic approach in major depressive disorder: an observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA trial)","volume":"22","author":"Minelli","year":"2021","journal-title":"Trials"},{"issue":"13","key":"10.1016\/j.euroneuro.2025.08.003_bib0043","first-page":"1","article-title":"Multi-gene pharmacogenomic testing that includes decision-support tools to guide medication selection for major depression: a health technology assessment","volume":"21","year":"2021","journal-title":"Ont. Health Technol. Assess. Ser."},{"issue":"n71","key":"10.1016\/j.euroneuro.2025.08.003_bib0044","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.euroneuro.2025.08.003_bib0045","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/cts.12986","article-title":"Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: a randomized controlled trial","volume":"14","author":"Papastergiou","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.113514","article-title":"The effect of loneliness on distinct health outcomes: a comprehensive review and meta-analysis","volume":"294","author":"Park","year":"2020","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0047","doi-asserted-by":"crossref","DOI":"10.1177\/10731911251326399","article-title":"Heterogeneity in item content of quality of life assessments used in depression psychotherapy research","author":"Peipert","year":"2025","journal-title":"Assessment."},{"issue":"2","key":"10.1016\/j.euroneuro.2025.08.003_bib0048","first-page":"151","article-title":"A new intervention for implementation of pharmacogenetics in psychiatry: a description of the PSY-PGx clinical study","volume":"17","author":"Pelgrim","year":"2024","journal-title":"Pharm. (Basel)"},{"issue":"1","key":"10.1016\/j.euroneuro.2025.08.003_bib0049","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jad.2011.03.027","article-title":"Two-year course of depressive and anxiety disorders: results from the Netherlands Study of Depression and Anxiety (NESDA)","volume":"133","author":"Penninx","year":"2011","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.euroneuro.2025.08.003_bib0050","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12888-017-1412-1","article-title":"Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial","volume":"17","author":"P\u00e9rez","year":"2017","journal-title":"BMC. Psychiatry"},{"issue":"11","key":"10.1016\/j.euroneuro.2025.08.003_bib0051","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s00213-017-4622-9","article-title":"Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder","volume":"234","author":"Peterson","year":"2017","journal-title":"Psychopharmacol. (Berl,)"},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0052","unstructured":"Popay, J., Roberts, H., Sowden, A., Petticrew, M., Arai, L., Rodgers, M., Britten, N., Roen, K., & Duffy, S. (2006). Guidance on the conduct of narrative synthesis in systematic reviews: a product from the ESRC Methods Programme. https:\/\/doi.org\/10.13140\/2.1.1018.4643."},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0053","article-title":"Introduction to the GRADE tool for rating certainty in evidence and recommendations","volume":"25","author":"Prasad","year":"2024","journal-title":"Clin. Epidemiol. Glob. Health"},{"issue":"5","key":"10.1016\/j.euroneuro.2025.08.003_bib0054","article-title":"Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder","volume":"3","author":"Rosa","year":"2007","journal-title":"Clin. Pract. Epidemiol. Ment. Health: CP EMH"},{"issue":"6","key":"10.1016\/j.euroneuro.2025.08.003_bib0055","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4088\/JCP.15r10583","article-title":"Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies","volume":"78","author":"Rosenblat","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0056","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jad.2018.08.056","article-title":"The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis","volume":"241","author":"Rosenblat","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0057","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12874-015-0091-1","article-title":"Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies","volume":"15","author":"R\u00f6ver","year":"2015","journal-title":"BMC. Med. Res. Methodol."},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2019.105910","article-title":"Results of the CYP-GUIDES randomized controlled trial: total cohort and primary endpoints","volume":"89","author":"Rua\u00f1o","year":"2020","journal-title":"Contemp. Clin. Trials"},{"issue":"11","key":"10.1016\/j.euroneuro.2025.08.003_bib0059","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0060","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jad.2024.09.041","article-title":"Drug metabolizing enzymes pharmacogenetic variation-informed antidepressant therapy approach for common mental disorders: a systematic review and meta-analysis","volume":"367","author":"Santenna","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.euroneuro.2025.08.003_bib0061","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/s13063-023-07361-6","article-title":"The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care","volume":"24","author":"Saya","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0062","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jad.2024.07.054","article-title":"Functioning in patients with major depressive disorder in remission: a systematic review and meta-analysis","volume":"363","author":"Schwarz","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"10","key":"10.1016\/j.euroneuro.2025.08.003_bib0063","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1176\/appi.ps.005012012","article-title":"Measures of personal recovery: a systematic review","volume":"64","author":"Shanks","year":"2013","journal-title":"Psychiatr. Serv."},{"issue":"2","key":"10.1016\/j.euroneuro.2025.08.003_bib0064","doi-asserted-by":"crossref","first-page":"150","DOI":"10.9758\/cpn.2015.13.2.150","article-title":"Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report","volume":"13","author":"Singh","year":"2015","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105009","article-title":"Clinical implementation of preemptive pharmacogenomics in psychiatry","volume":"101","author":"Skokou","year":"2024","journal-title":"EBioMedicine"},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2025.08.003_bib0066","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41397-022-00295-3","article-title":"Meta-analysis of pharmacogenetic clinical decision support systems for the treatment of major depressive disorder","volume":"23","author":"Skryabin","year":"2023","journal-title":"Pharmacogenomics. J."},{"issue":"2","key":"10.1016\/j.euroneuro.2025.08.003_bib0067","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/070674370605100206","article-title":"Prevalence and incidence studies of anxiety disorders: a systematic review of the literature","volume":"51","author":"Somers","year":"2006","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0068","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0069","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2288-14-30","article-title":"Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference?","volume":"14","author":"Takeshima","year":"2014","journal-title":"BMC. Med. Res. Methodol."},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0070","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1276410","article-title":"Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis","volume":"15","author":"Tesfamicael","year":"2024","journal-title":"Front. Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2025.08.003_bib0071","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/npp.2011.306","article-title":"Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review","volume":"37","author":"Undurraga","year":"2012","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.euroneuro.2025.08.003_bib0072","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/JCP.0000000000001129","article-title":"Effects of pharmacogenetic screening for CYP2D6 among elderly starting therapy with Nortriptyline or Venlafaxine: a pragmatic randomized controlled trial (CYSCE Trial)","volume":"39","author":"van der Schans","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0073","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fpsyt.2020.00094","article-title":"Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going?","volume":"11","author":"van Westrhenen","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0074","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.640032","article-title":"Policy and practice review: a first guideline on the use of pharmacogenetics in clinical psychiatric practice","volume":"12","author":"van Westrhenen","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2025.08.003_bib0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/wps.21289","article-title":"PSY-PGx: a new intervention for the implementation of pharmacogenetics in psychiatry","volume":"24","author":"van Westrhenen","year":"2025","journal-title":"World Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2025.08.003_bib0076","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3102\/10769986030003261","article-title":"Bias and efficiency of meta-analytic variance estimators in the random-effects model","volume":"30","author":"Viechtbauer","year":"2005","journal-title":"J. Educ. Behav. Stat."},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0077","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"issue":"7","key":"10.1016\/j.euroneuro.2025.08.003_bib0078","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3109\/07853890.2011.583675","article-title":"Therapeutic options in treatment-resistant depression","volume":"43","author":"Vieta","year":"2011","journal-title":"Ann, Med"},{"issue":"9","key":"10.1016\/j.euroneuro.2025.08.003_bib0079","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/pharmaceutics11090453","article-title":"Effectiveness of a pharmacogenetic tool at improving treatment efficacy in major depressive disorder: a meta-analysis of three clinical studies","volume":"11","author":"Vilches","year":"2019","journal-title":"Pharmaceutics."},{"issue":"1","key":"10.1016\/j.euroneuro.2025.08.003_bib0080","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12888-023-04756-2","article-title":"Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT","volume":"23","author":"Wang","year":"2023","journal-title":"BMC. Psychiatry"},{"issue":"6","key":"10.1016\/j.euroneuro.2025.08.003_bib0081","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/acps.13541","article-title":"Antidepressants and quality of life in patients with major depressive disorder\u2014Systematic review and meta-analysis of double-blind, placebo-controlled RCTs","volume":"147","author":"Wiesinger","year":"2023","journal-title":"Acta Psychiatr. Scand."},{"issue":"11","key":"10.1016\/j.euroneuro.2025.08.003_bib0082","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11920-021-01290-4","article-title":"Correlates of quality of life in anxiety disorders: review of recent research","volume":"23","author":"Wilmer","year":"2021","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0083","doi-asserted-by":"crossref","DOI":"10.1016\/j.infsof.2022.106908","article-title":"Successful combination of database search and snowballing for identification of primary studies in systematic literature studies","volume":"147","author":"Wohlin","year":"2022","journal-title":"Inf. Softw. Technol."},{"key":"10.1016\/j.euroneuro.2025.08.003_bib0232","unstructured":"World Health Organisation. (2019). International classification of diseases for mortality and morbidity statistics (11th revision). https:\/\/icd.who.int."},{"issue":"1","key":"10.1016\/j.euroneuro.2025.08.003_bib0085","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1176\/appi.ajp.163.1.148","article-title":"How should remission from depression be defined? The depressed patient\u2019s perspective","volume":"163","author":"Zimmerman","year":"2006","journal-title":"Am. J. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X25001531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X25001531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T23:12:04Z","timestamp":1760742724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X25001531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":86,"alternative-id":["S0924977X25001531"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.08.003","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}